This inventor holds 3 USPTO granted patents and 8 published patent applications, plus 4 CIPO patents and 1 EPO patent. Top assignees: Alfa Wassermann, Inc., Alfasigma S.p.a.. Active years: 2012-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2012-2019
Title: Giuseppe Bottoni: Innovator in Pharmaceutical Formulations
Introduction
Giuseppe Bottoni is a notable inventor based in Bologna, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the stabilization of polymorphous forms of rifaximin. With a total of 3 patents, his work has implications for the development of stable pharmaceutical products.
Latest Patents
One of his latest patents focuses on the use of polyols to obtain stable polymorphous forms of rifaximin. This invention describes how polyols, which contain at least two hydroxy groups, can be added to rifaximin powder to stabilize the β form. The stability of this polymorph is maintained over time, regardless of environmental humidity. The patent outlines a method for preparing formulations that consist of pure and stable polymorphous forms, which are essential for creating effective pharmaceutical products.
Career Highlights
Throughout his career, Giuseppe Bottoni has worked with prominent companies in the pharmaceutical industry, including Alfa Wassermann S.p.a. and Alfasigma S.p.a. His experience in these organizations has allowed him to refine his expertise in pharmaceutical formulations and innovations.
Collaborations
Giuseppe has collaborated with several professionals in his field, including Paola Maffei and Milena Bachetti. These collaborations have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Giuseppe Bottoni's innovative work in stabilizing polymorphous forms of rifaximin showcases his significant contributions to the pharmaceutical industry. His patents and collaborations reflect his commitment to advancing pharmaceutical formulations, ultimately benefiting the field and its applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
